Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pdl Biopharma Inc (PDLI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 382,444
  • Shares Outstanding, K 165,560
  • Annual Sales, $ 244,300 K
  • Annual Income, $ 63,610 K
  • 36-Month Beta 0.49
  • Price/Sales 1.51
  • Price/Cash Flow 5.38
  • Price/Book 0.49

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.00 +16.00%
on 04/11/17
2.35 -1.28%
on 04/27/17
+0.27 (+13.17%)
since 03/27/17
3-Month
1.96 +18.37%
on 03/24/17
2.35 -1.28%
on 04/27/17
+0.07 (+3.11%)
since 01/27/17
52-Week
1.93 +20.21%
on 12/20/16
3.82 -39.27%
on 04/29/16
-1.46 (-38.62%)
since 04/27/16

Most Recent Stories

More News
PDL BioPharma to Announce First Quarter 2017 Financial Results on May 3, 2017

PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its first quarter 2017 financial results for the period ended March 31, 2017, on Wednesday, May 3,...

PDLI : 2.32 (+0.43%)
PDL BioPharma Announces Settlement of Keytruda Patent Infringement Lawsuit with Merck

PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that on April 21, 2017, the Company entered into a settlement agreement with certain subsidiaries of Merck & Co., Inc. ("Merck")...

PDLI : 2.32 (+0.43%)
MRK : 62.79 (+0.14%)
Biotech Stocks on Investors' Radar -- Halozyme Therapeutics, Cara Therapeutics, PDL BioPharma, and Arena Pharma

On Wednesday, benchmark US indices were in bearish colors as the NASDAQ Composite closed the trading session down 0.52%; the Dow Jones Industrial Average edged 0.29% lower; and the S&P 500 was down 0.38%....

CARA : 15.65 (-1.94%)
PDLI : 2.32 (+0.43%)
ARNA : 1.38 (-0.72%)
HALO : 13.94 (+0.43%)
PDL BioPharma to Hold Annual Meeting of Stockholders on June 9, 2017

PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will hold its annual meeting of stockholders on Friday, June 9, 2017, at 10:00 a.m. Pacific Time for all stockholders...

PDLI : 2.32 (+0.43%)
Clinical Trial Advancements With Positive Data for Phase 1 and 2 Results Fueling Steady Growth in Biomedical Industry

PALM BEACH, Florida, April 4, 2017 /PRNewswire/ --

RP.VN : 0.960 (+3.23%)
WMGI : 30.45 (-0.07%)
NVCR : 11.10 (+1.37%)
PDLI : 2.32 (+0.43%)
REPCF : 0.7070 (+3.17%)
COOL : 12.29 (+3.10%)
Clinical Trial Advancements With Positive Data for Phase 1 and 2 Results Fueling Steady Growth in Biomedical Industry

MarketNewsUpdates.com News Commentary

RP.VN : 0.960 (+3.23%)
WMGI : 30.45 (-0.07%)
NVCR : 11.10 (+1.37%)
REPCF : 0.7070 (+3.17%)
PDLI : 2.32 (+0.43%)
COOL : 12.29 (+3.10%)
WMGIZ : 1.41 (+0.71%)
PDL BioPharma (PDLI) Up 5.9% Since Earnings Report: Can It Continue?

PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PDLI : 2.32 (+0.43%)
Today's Research Reports on Stocks to Watch: Celldex Therapeutics and PDL BioPharma

NEW YORK, NY / ACCESSWIRE / March 31, 2017 / Celldex Therapeutics' stock might be plummeting but Wall Street still remains adamant that the company's stock could rise significantly in value. The company's...

CLDX : 3.36 (-0.59%)
PDLI : 2.32 (+0.43%)
PDL BioPharma to Present at Two Upcoming Investor Conferences

PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, PDL's president and chief executive officer, will present at two investor conferences in March.

PDLI : 2.32 (+0.43%)
PDL BioPharma Partnering Deals and Alliances 2010 to 2017

This report provides all the information you require to better understand PDL BioPharma and its partnering interests and activities since 2010.

PDLI : 2.32 (+0.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital...

See More

Support & Resistance

2nd Resistance Point 2.40
1st Resistance Point 2.36
Last Price 2.32
1st Support Level 2.24
2nd Support Level 2.16

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.